Compugen Taps Biotech Veteran to Steer AI-Driven Cancer Pipeline

HOLON, Israel – February 12, 2026 – Compugen Ltd., a clinical-stage company at the forefront of using artificial intelligence to discover cancer immunotherapies, has appointed Dr. Michele Holcomb to its Board of Directors. The move, effective February 11, is a significant strategic enhancement, bringing a three-decade veteran with deep experience in corporate strategy, R&D management, and value creation to a company poised at a critical inflection point.

Dr. Holcomb's appointment is being interpreted by industry observers as a deliberate move to bolster the company's leadership with the commercial and strategic acumen needed to translate its advanced computational science into tangible clinical and shareholder value. As Compugen advances its pipeline, headlined by partnerships with pharmaceutical giants AstraZeneca and Gilead, the addition of a director with Dr. Holcomb's track record signals a maturing strategy focused on execution and growth.

A Strategic Powerhouse for an AI Pioneer

Dr. Holcomb’s career is a blueprint for the modern biotech leader, blending a deep scientific foundation with high-level corporate strategy. Holding a Ph.D. in chemistry from the University of California, Berkeley, and starting her career as an R&D chemist, she possesses a fundamental understanding of the scientific process. However, it is her extensive experience in the corporate world that makes her an exceptional addition to Compugen's board.

Her resume includes 15 years at McKinsey & Company, where she was a Partner and a co-founder of the firm's biotech practice, advising top-tier pharmaceutical and emerging biotech companies. This was followed by a pivotal role at Teva Pharmaceuticals as Chief Operating Officer of Global R&D and SVP of Strategy, where she was directly responsible for pipeline portfolio management, including the crucial tasks of licensing, acquisitions, and alliance management.

More recently, she served as Executive Vice President and Chief Strategy and Business Development Officer at the healthcare giant Cardinal Health. In this capacity, she was tasked with defining enterprise-wide strategy, identifying growth opportunities, and executing investments and acquisitions. This experience in navigating a complex, evolving healthcare landscape provides her with a unique perspective on how to position assets for long-term success.

"Michele brings more than three decades of experience spanning the biotech, pharmaceuticals and healthcare services industries," said Dr. Anat Cohen-Dayag, Executive Chair of Compugen, in a statement. "Her unique blend of strategic insights, corporate development, innovation and firsthand operational experience across multiple executive roles makes her an exceptional addition to Compugen." Dr. Cohen-Dayag emphasized that Dr. Holcomb's ability to "guide organizations through value-creating inflection points will meaningfully strengthen the board."

Navigating the Biotech Inflection Point

The timing of Dr. Holcomb’s appointment is particularly noteworthy. Compugen enters 2026 claiming a "position of financial strength," armed with a pipeline of promising, first-in-class drug candidates discovered through its proprietary AI/ML platform, Unigen™. The company is no longer just an early-stage discovery engine; it is managing a portfolio of clinical assets at various stages of development, several of which are tied to major industry players.

This includes two differentiated programs targeting TIGIT, a hot target in immuno-oncology. The first, COM902, is a wholly-owned antibody in Phase 1 development. The second is rilvegostomig, a bispecific antibody being advanced into Phase 3 trials by AstraZeneca, a partnership that provides significant external validation for Compugen's discovery platform. The TIGIT component of AstraZeneca's drug is derived from Compugen's COM902, linking the two programs.

Beyond TIGIT, Compugen has COM701, a potential first-in-class antibody targeting PVRIG, and GS-0321, an anti-IL-18 binding protein antibody licensed to Gilead Sciences. Having partnerships with both AstraZeneca and Gilead on assets discovered in-house is a rare and enviable position for a clinical-stage biotech. However, managing these high-stakes collaborations and maximizing the value of its wholly-owned programs requires sophisticated strategic oversight.

Dr. Cohen-Dayag noted this challenge, stating the belief that Dr. Holcomb's expertise will be "instrumental... in helping us convert these opportunities into long-term value for patients and shareholders." Dr. Holcomb’s experience in portfolio management and alliance management at Teva is directly applicable to Compugen's current situation, providing the board with the insight needed to make critical decisions about which programs to accelerate, partner, or prioritize.

The Evolving Biotech Boardroom: Beyond the Lab Coat

Dr. Holcomb's appointment also reflects a broader trend in the life sciences industry. As biotech companies become more technologically complex, leveraging AI, machine learning, and vast datasets, their governance needs are evolving. Boards can no longer be composed solely of esteemed scientists and clinicians; they require a diverse mix of skills that includes deep strategic, financial, and commercial expertise.

Dr. Holcomb is the embodiment of this new archetype of biotech director. She is fluent in the language of science but also in the language of business strategy, corporate finance, and market dynamics. Her current board positions at PureTech Health, a clinical-stage biotherapeutics company, and Kimball Electronics, a global manufacturing solutions provider, further underscore her reputation as a sought-after director capable of guiding technology-driven organizations.

In her own words, Dr. Holcomb expressed her enthusiasm for the company's unique position. "I am honored to join the Board of Directors of Compugen, which has repeatedly demonstrated its ability to generate and advance differentiated programs for the treatment of cancer," she stated. "The combination of scientific innovation, strategic focus and a disciplined approach to partnering creates a compelling platform for sustained value creation."

By bringing Dr. Holcomb into its inner circle, Compugen is sending a clear message to investors and partners. The company recognizes that its future success depends not only on the power of its AI discovery engine but also on the strategic wisdom of its leadership. This appointment equips Compugen with a seasoned navigator as it steers its innovative pipeline through the complex and final stages of clinical development toward potential commercialization.